New MS Drug Yields Mixed Results in Study
Relapse rates with daclizumab were lower than with a standard therapy, but side effects were greaterContinue Reading
Relapse rates with daclizumab were lower than with a standard therapy, but side effects were greaterContinue Reading
Smokers were twice as likely as nonsmokers to resume drinking, study findsContinue Reading
Long-acting drug injected every four-to-six weeks
Continue Reading
Long-acting drug injected every four-to-six weeks
Continue Reading
Emits electric pulses designed to thwart tumor growth
Continue Reading
Anal, colon and liver cancers more common now, researchers findContinue Reading
Study suggests about 57 percent of hospitalizations for flu-related pneumonia might be preventedContinue Reading
Study found those without heart problems faced higher chances of heart trouble after non-cardiac operationsContinue Reading
Helps immune system fight non-small cell lung cancerContinue Reading
Keytruda shrank tumors in some patients with advanced diseaseContinue Reading
© 2021 WeeklyMD.com - All Rights Reserved.